20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Gainers

• Seneca Biopharma, Inc. SNCA shares moved upwards by 27.78% to $1.05 during Thursday's pre-market session.

• Aurora Cannabis, Inc. ACB shares increased by 25.80% to $16.04. The most recent rating by Piper Sandler, on May 15, is at Neutral, with a price target of $10.

• IMV, Inc. IMV shares increased by 20.48% to $4. The most recent rating by Wells Fargo, on May 18, is at Overweight, with a price target of $8.

• Alterity Therapeutics, Inc. ATHE shares rose 10.75% to $0.72.

• Aquestive Therapeutics, Inc. AQST stock moved upwards by 5.99% to $6.55.

• Guardion Health Sciences, Inc. GHSI stock moved upwards by 5.75% to $0.52.

• Aldeyra Therapeutics, Inc. ALDX stock moved upwards by 5.26% to $4.60. The most recent rating by Oppenheimer, on May 12, is at Outperform, with a price target of $12.

• Altimmune, Inc. ALT stock rose 4.95% to $6.36.

• HEXO, Inc. HEXO stock moved upwards by 4.66% to $0.51. The most recent rating by Roth Capital, on Mar 31, is at Neutral, with a price target of $1.

• Midatech Pharma, Inc. MTP shares moved upwards by 4.61% to $1.59.

Losers

• Akorn, Inc. AKRX stock declined 24.97% to $0.21 during Thursday's pre-market session.

• scPharmaceuticals, Inc. SCPH shares fell 17.82% to $8.90. The most recent rating by HC Wainwright & Co., on May 13, is at Buy, with a price target of $15.

• Synlogic, Inc. SYBX stock decreased by 10.29% to $2.18.

• Flexion Therapeutics, Inc. FLXN shares decreased by 9.80% to $9.85. The most recent rating by Needham, on May 8, is at Buy, with a price target of $20.

• Entera Bio, Inc. ENTX shares fell 8.77% to $2.60.

• Surface Oncology, Inc. SURF shares fell 8.51% to $3.55.

• Miragen Therapeutics, Inc. MGEN shares fell 8.30% to $0.58.

• Ekso Bionics Holdings, Inc. EKSO shares decreased by 7.41% to $3. The most recent rating by Aegis Capital, on Apr 13, is at Buy, with a price target of $15.

• DBV Technologies, Inc. DBVT shares fell 6.53% to $4.58. The most recent rating by Citigroup, on Apr 6, is at Buy, with a price target of $10.

• Galapagos, Inc. GLPG stock fell 6.01% to $207.98. The most recent rating by Morgan Stanley, on Apr 15, is at Equal-Weight, with a price target of $226.